Efficacy of docetaxel addition to next‐generation androgen receptor‐axis‐targeted therapies and androgen deprivation therapy in metastatic hormone‐sensitive prostate cancer: A tumor volume‐specific analysis
Patients with mHSPC did not show significant improvement with docetaxel addition to ARAT-based regimens, regardless of tumor volume. Further research is needed to identify potential beneficiaries of this combination therapy.
Authors
- Shohei Fukuda (ORCID: https://orcid.org/0000-0003-2741-8338)
- Hajime Tanaka (ORCID: https://orcid.org/0000-0003-3632-2901)
- Yuma Waseda (ORCID: https://orcid.org/0000-0002-9319-1373)
- Soichiro Yoshida (ORCID: https://orcid.org/0000-0003-2757-8083)
- Noriyoshi Miura (ORCID: https://orcid.org/0000-0002-2229-0948)
- Yasuhisa Fujii (ORCID: https://orcid.org/0000-0002-6761-3229)
- Wei Chen (ORCID: https://orcid.org/0000-0003-2275-4527)
Institutions
- Zigong First People's Hospital (CN)
- Ehime University (JP)
- Institute of Science Tokyo (JP)
Publication Details
- Journal
- International Journal of Urology
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1111/iju.15657
- Citations
- 16
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 6.70
Funders
- Sichuan Province Science and Technology Support Program